Clinical Trials on Essential Hypertension in Argentina

Total 115 results

Istituto Auxologico Italiano

Recruiting

Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System (CHARGE-APP)

Hypertension,Essential | Hypertension, Uncontrolled

Argentina, China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Finland, Norway, Sweden, France, Germany, Italy, Turkey, Argentina, Chile, Ecuador, Spain, Switzerland
Novartis

Completed

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Hypertension

United States, Argentina, Colombia, France, Germany, India, Spain
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Takeda

Completed

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Argentina, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Hypertension

Spain, Italy, Netherlands, United States, Denmark, Taiwan, Argentina, Germany, Russian Federation, Slovakia, Canada, Hungary, Latvia, Lithuania, Poland, Finland, France, Sweden
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Bayer

Completed

Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs (START)

Pulmonary Arterial Hypertension

Argentina
Hospital Italiano de Buenos Aires

Withdrawn

Pulmonary Hypertension Institutional Registry (RIHP)

Death

Argentina
Tulane University
National Heart, Lung, and Blood Institute (NHLBI); Institute for Clinical Effectiveness...

Completed

Hypertension Control Program in Argentina (HCPIA)

Hypertension

Argentina
Sanofi

Completed

Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina (RAFEHELP)

Hypertension

Argentina
Alcon Research

Completed

Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma

Glaucoma

Argentina
Estudios Clínicos Latino América
Population Health Research Institute

Recruiting

The ECLA/PHRI Intervention in the Community Trial (EPIC)

Hypertension

Argentina
AstraZeneca

Completed

To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension (ADHERENCE)

Hypertension

Argentina
Laboratorios Poen

Completed

Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost

Primary Open-angle Glaucoma

Argentina
Hospital Italiano de Buenos Aires

Completed

Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol (CHAB)

Hypertension | Metabolic Syndrome

Argentina
Institute of Nutrition of Central America and Panama
Universidad Peruana Cayetano Heredia; RAND; Institute for Clinical Effectiveness...

Terminated

Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings

Hypertension | Prehypertension

Argentina, Peru, Guatemala
School of Medicine. National University of Cuyo

Recruiting

Argentine Registry of Lp(a) (GAELpa)

Cardiovascular Diseases | Hypertension | Hypercholesterolemia | Diabete Type 2 | Lp(A)

Argentina
Universidad de la Republica
Hospital Italiano de Buenos Aires; KU Leuven

Withdrawn

Telemonitoring of Uncontrolled Hypertension (ERNESTINA)

Hypertension

Argentina, Uruguay
Asociacion Latinoamericana de Torax
Ferrer Internacional S.A.; Bayer; Actelion

Unknown

Latin American Pulmonary Hypertension Registry (RELAHP)

Pulmonary Hypertension

Uruguay, Honduras, Argentina, Brazil, Chile, Colombia, Mexico, Venezuela
Novartis Pharmaceuticals

Recruiting

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

Pulmonary Arterial Hypertension

Spain, Germany, Netherlands, Poland, United Kingdom, Argentina, United States
Institute for Clinical Effectiveness and Health...
Inter-American Development Bank

Completed

Effect of Peer Mentoring and Blood Pressure Self-monitoring on Hypertension Control.

Hypertension

Argentina
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Hypertension

Sweden, Slovakia, Argentina, Germany, Turkey, Norway, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Germany, Poland, United Kingdom, Netherlands, Argentina
Novartis

Completed

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension (ACQUIRE)

Hypertension

Switzerland, Italy, Argentina, Germany, Turkey, United States, Ecuador, Guatemala
Gilead Sciences

Completed

A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Pulmonary Arterial Hypertension

Argentina, Brazil, Chile, Mexico
Bayer

Completed

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (EXPERT)

Hypertension, Pulmonary

Turkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
Laboratorios Poen

Recruiting

Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

Ocular Hypertension | Glaucoma, Open-Angle

Argentina
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
International CTEPH Association
Janssen Pharmaceuticals

Recruiting

TrEatment Approach in the Multimodal Era Registry (TEAM)

Chronic Thromboembolic Pulmonary Hypertension | CTEPH

United States, Denmark, Belgium, Canada, Japan, Argentina, Italy, Austria, Poland, India, Spain, Mexico, United Kingdom, China, Brazil, Turkey, Germany, Singapore, Colombia
GlaxoSmithKline

Completed

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

Hypertension, Pulmonary

France, United States, Germany, Spain, Italy, Japan, Hungary, Russian Federation, Argentina
Italian Institute of Telemedicine
BPLab

Completed

International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring (VASOTENS)

Hypertension

Russian Federation, Argentina, Armenia, Australia, Italy, Kazakhstan, Mexico, Portugal, Romania, Ukraine
Pfizer

Terminated

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Bulgaria, Argentina, Chile, China, Colombia, Czech Republic, India, Malaysia, Mexico, Peru, Romania, Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine
Actelion

Terminated

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants (CARE PAH)

Pulmonary Arterial Hypertension

United States, Germany, Korea, Republic of, United Kingdom, China, Canada, Netherlands, Italy, Japan, Poland, Spain, Brazil, Malaysia, Argentina, Singapore, Puerto Rico, Sweden
Actelion

Terminated

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (RESTORE)

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, Israel, Singapore, United States, Russian Federation, Brazil, Netherlands, Malaysia, Saudi Arabia, United Kingdom, Hong Kong, France, United Arab Emirates, Argentina
Gilead Sciences

Completed

Study of Ambrisentan in Participants With Pulmonary Hypertension (ABS-LT)

Pulmonary Hypertension

United States, Australia, Argentina, Canada, Mexico, Brazil, Chile, Russian Federation, Ukraine
GlaxoSmithKline

Terminated

Efficacy and Safety of Ambrisentan in Children 8-18yrs

Hypertension, Pulmonary

France, United States, Germany, Spain, Italy, Japan, Hungary, Russian Federation, Argentina
AstraZeneca

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxAsia)

Resistant Hypertension | Uncontrolled Hypertension

Argentina, China, Korea, Republic of, Vietnam, Japan, Philippines, Hong Kong, Turkey, India, Australia, Russian Federation
United Therapeutics

Terminated

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY)

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease | Connective Tissue Disease

Spain, United States, Australia, Canada, United Kingdom, Italy, Argentina, Austria, Belgium, Brazil, Germany, Poland
Sanofi

Completed

ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination (ACTUAL)

Hypertension

Brazil, Tunisia, Argentina, Egypt, Mexico, Peru, Morocco, Colombia, Guatemala, Venezuela, Lebanon, Algeria, Ecuador, Panama, Saudi Arabia, United Arab Emirates
GlaxoSmithKline

Terminated

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (AMBER II)

Hypertension

Spain, Germany, Korea, Republic of, Canada, Japan, Netherlands, United Kingdom, Czechia, United States, China, Austria, Israel, Argentina, Russian Federation, Mexico, Saudi Arabia
GlaxoSmithKline

Terminated

Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (AMBER I)

Hypertension

Spain, Germany, Korea, Republic of, Canada, Japan, Netherlands, United Kingdom, United States, China, Austria, Israel, Argentina, Russian Federation, Mexico, Saudi Arabia, Czech Republic
Insmed Incorporated

Completed

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension

Belgium, Germany, Spain, Argentina, Australia, Italy, United Kingdom
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Pulmonary Hypertension | Interstitial Lung Disease

Belgium, Germany, Spain, Italy, Argentina, Australia, United Kingdom
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Argentina, Austria, Brazil, Germany, Italy, Malaysia, Philippines, Spain, United Kingdom, Serbia, Japan, United States, Mexico, Denmark

Clinical Trials on Essential Hypertension in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations